The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IRONMAN: The international registry for men with advanced prostate cancer.
 
Daniel J. George
Leadership - Capio BioSciences
Honoraria - Acceleron Pharma; American Association for Cancer Research; Axess Oncology; Bayer; EMD Serono; Exelixis; Janssen Oncology; Millennium Medical Publishing; OncLive; Pfizer; Sanofi; UroToday
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Constellation Pharmaceuticals; Exelixis; Genentech; Innocrin Pharma; Janssen; Merck Sharp & Dohme; Michael J. Hennessy Associates; Myovant Sciences; Pfizer; Physicans' Education Resource; Propella Therapeutics; RevHealth; Sanofi
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Dendreon (Inst); Exelixis (Inst); Innocrin Pharma (Inst); Janssen Oncology (Inst); Novartis (Inst); Pfizer (Inst); Sanofi/Aventis (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Janssen Oncology; Merck; Pfizer; Sanofi; UroToday
 
Lorelei A Mucci
Employment - Convergent Therapeutics (I)
Stock and Other Ownership Interests - Candel Therapeutics (I); Seer (I)
Consulting or Advisory Role - Immunis.AI (I); Merck (I); SynDevRx (I); Tarveda Therapeutics (I); Veru (I)
Research Funding - AstraZeneca; Janssen
Expert Testimony - Bayer
 
Philip W. Kantoff
Employment - Convergent Therapeutics
Leadership - Context Therapeutics; Convergent Therapeutics; XLink
Stock and Other Ownership Interests - Cogent Biosciences; Context Therapeutics; Druggablity Technologies; Mirati Therapeutics; Placon; PrognomIQ; Seer; SynDevRx; XLink
Consulting or Advisory Role - Anji Pharma; Candel Therapeutics; Context Therapeutics; Druggablity Technologies; Genentech/Roche; Janssen; Merck; OncoCellMDX; Progenity; PrognomIQ; Seer; SynDevRx; Tarveda Therapeutics; Veru; XLink
Patents, Royalties, Other Intellectual Property - Chromosome Copy Number Gain as a Biomarker of Urothelial Carcinoma Lethality; Composition and Methods for Screening and Diagnosis of Prostate Cancer; Drug Combinations to Treat Cancer; Method for Predicting the Risk of Prostate Cancer Morbidity and Mortality; Methods and Kits for Determining Sensitivity to Cancer Treatment; Methods for Predicting Likelihood of Responding to Treatment; Predicting and Treating Prostate Cancer; Somatic ERCC2 Mutations Correlate with Cisplatin sensitivity in muscle-invasive Urothelial Carcinoma (Patent); Up-to-Date Royalties; Wolters Kluwer Royalties
Other Relationship - Bayer (I)
 
Paul Villanti
No Relationships to Disclose
 
Jake Vinson
No Relationships to Disclose
 
Travis A. Gerke
No Relationships to Disclose
 
Terry Hyslop
Consulting or Advisory Role - Abbvie
Travel, Accommodations, Expenses - Abbvie
 
Emily Rencsok
No Relationships to Disclose